Reduced Brain Somatostatin Levels in Alzheimer's Disease

C. A. Tamminga, N. L. Foster, T. N. Chase

Research output: Contribution to journalLetter

19 Scopus citations

Abstract

To the Editor: Pharmacologic attempts to reverse symptoms of Alzheimer's dementia have thus far lacked conspicuous success. Most recent therapeutic strategies have been designed to correct a cholinergic loss arising from degeneration of acetylcholine-containing neuronal projections to the cerebral cortex. However, the widespread distribution of cholinergic depletion in Alzheimer's dementia1 does not correlate with the focal distribution of functional brain abnormalities in this disorder, as determined by positron emission tomography with fluorodeoxyglucose (PET/FDG).2 Thus, there is reason to suspect that stimulation of cholinergic transmission might not reverse a functionally relevant defect in the dementia. Imaging studies with PET/FDG suggest a.

Original languageEnglish (US)
Pages (from-to)1294-1295
Number of pages2
JournalNew England Journal of Medicine
Volume313
Issue number20
DOIs
StatePublished - Nov 14 1985

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Reduced Brain Somatostatin Levels in Alzheimer's Disease'. Together they form a unique fingerprint.

  • Cite this